Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e72-4. doi: 10.1097/QAI.0b013e31828e6182.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Chemokine CCL2 / blood*
  • Chemokine CXCL10 / blood
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / complications
  • Immune Reconstitution Inflammatory Syndrome / diagnosis*
  • Interleukin-18 / blood
  • Interleukin-8 / blood
  • Lipopolysaccharide Receptors / blood
  • Macrophage Activation
  • Mycobacterium tuberculosis / immunology
  • Neutrophil Activation
  • Prognosis
  • Tuberculosis / complications
  • Tuberculosis / immunology*

Substances

  • Anti-HIV Agents
  • CCL2 protein, human
  • CXCL10 protein, human
  • CXCL8 protein, human
  • Chemokine CCL2
  • Chemokine CXCL10
  • Interleukin-18
  • Interleukin-8
  • Lipopolysaccharide Receptors